Metsera's Once Monthly GLP-1 Shot Looking Better than Zepbound in Early Trials Dave Knapp Jan 8, 2025 3 min read Metsera, the biopharma startup backed by $500 million in venture capital, has released fresh data on its lead obesity candidate, MET-097i
The indication is acquired and generalized hypoactive sexual desire disorder in premenopausal women
It is produced through the fermentation of bacteria, which results in the production of glutathione
This combination of appetite suppression and blood sugar control leads to more sustainable weight loss and healthier eating patterns
To start with, it will be available in the UK only on prescription privately and not free on the NHS
Limited coverage exists under specific employer-, plan-, and diagnosis-based conditions: Some employer and government plans offer coverage with prior authorization Coverage varies by employer, plan type, and diagnosis BCBS operates through independent state affiliates, so rules differ by state Who this guide is for BCBS members exploring Zepbound coverage through employer-sponsored plans, ACA marketplace plans, Medicare Advantage, or the Federal Employee Program (FEP)